期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

正确认识和应用肿瘤标记物 被引量：6

下载PDF
导出
摘要 2009年,在美国临床肿瘤协会（ASCO）年会上,Gordon Rustin代表欧洲协作组报告了MRCOV05和EORTC 55955临床随机试验的结果[1]。该临床试验发现仅有CA125升高的复发性卵巢癌立即开始化疗与延迟化疗相比生存期相同,但生活质量明显较差。
作者 崔恒 谢幸
机构地区 北京大学人民医院 浙江大学医学院附属妇产科医院
出处 《中国妇产科临床杂志》 2011年第5期321-323,共3页 Chinese Journal of Clinical Obstetrics and Gynecology
关键词 肿瘤标记物 临床随机试验 CA125升高 应用 复发性卵巢癌 2009年 EORTC 肿瘤协会
分类号 R730.4 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Rustin GJ, van den Burg M. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 levels alone versus delayed treatment based on conventional clinical indicators (MRC OV5/EORTC 55955 trials). J Clin Oncol, 2009, 27: 1.
  • 2Aggarwal P, Kehoe S. Serum turnnur markers in gynaecological cancers. Maturitas, 2010, 67: 46-53.
  • 3Anderson GL, Mclntosh M, Wu LL, et al. Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study. J Natl Cancer Inst, 2010, 102:26 - 38.
  • 4卢仁泉,郭林,沈烨红.HE4在卵巢癌诊治中的临床应用评价[J].中国癌症杂志,2010,20(9):680-685. 被引量：39
  • 5Demirtas E, Krishnamurthy S, Tulandi T. Elevated serum beta--human chorionic gonadotropin in nonpregnant conditions. Obstet Gynecol Surv, 2007, 62: 675-679.
  • 6Cole LA, Butler SA. Hyperglyeosylated human chorionic gonadotropin and human chorionie gonadotropin free beta-suhunit: tumor markers and tumor promoters. J Reprod Med, 2008, 53:499-512.
  • 7Iles RK. Ectopic hCG beta expression by epithelial cancer: malignant behaviour, metastasis and inhibition of tumor cell apoptosis. Mol Cell Endocrinol, 2007, 260 - 262,264 - 270.
  • 8Cole LA. Hyperglycosylated hCG, a review. Placenta, 2010, 31: 653- 664.

二级参考文献14

  • 1Drapkin R,Hecht JL.The origins of ovarian cancer,hurdles and progress[J].Women's Oncol Rev,2002,2(1):261-268.
  • 2Pickle LW,Hao Y,Jemal A,et el.A new method of estimating United States and state-level cancer incidence counts for the current calendar year[J].CA Cancer J Clin,2007,57(1):30-42.
  • 32007年上海市恶性肿瘤报告[M].上海市疾病预防控制中心编制,2007:5-7.
  • 4Riedinger J,Bonnetain F,Basuyau J,et al.Change in CA125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumor outcome[J].Ann Oncol,2007,18(5):881-885.
  • 5Buys SS,Partridge E,Greene MH,et al.Ovarian cancer screening in the prostate,lung,colorectal and ovarian(PLCO)cancer screening trial:Findings from the initial screen of a randomized trial[J].Am J Obstet Gynecol,2005,193(5):1630-1639.
  • 6Rosen DG,Wang L,Atkinson JN,et el.Potential markers that complement expression of CA125 in epithelial ovarian cancer[J].Gynecol Oncol,2005,99(1):267-277.
  • 7Drapkin R,Von Horsten HH,Lin YF,et al.Human epididymis protein 4(HE4)is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas[J].Cancer Res,2005,65(6):2162-2169.
  • 8Huhtinen K,Suvitie P,Hiissa J.Serum HE4 concentration differentiates malignant ovarian tumors from ovarian endometriotic cysts[J].Br J Cancer,2009,100(7):1315-1319.
  • 9Trape J,Olaguer JP,Buxo J,et el.Biological variation of tumor markers and its application in the detection of disease progression in patients with non-small cell lung cancer[J].Clinical Chemistry,2005,51(1):220-222.
  • 10Hellstrom I,Raycraft J,Hayden-Ledbetter M,et al.The HE4(WFDC2)protein is a biomarker for ovarian carcinoma[J].Cancer Res,2003,63(13):3695-3700.

共引文献38

同被引文献38

  • 1王悦,刘隆忠,周建华,裴小青,陈孝岳.经阴道彩色多普勒超声与多项血清肿瘤标志物联合诊断卵巢肿瘤的价值[J].癌症,2004,23(z1):1585-1588. 被引量：3
  • 2任义敏,李国杰.彩色多普勒超声诊断卵巢肿瘤的价值[J].中国临床保健杂志,2005,8(4):322-323. 被引量：3
  • 3郎景和,丁晓曼.当前妇科肿瘤临床诊治的特点和问题[J].癌症进展,2006,4(1):2-6. 被引量：24
  • 4Kobayashi E, Ueda Y, Matsuzaki S, et al. Biornarkers for Screen- ing, Diagnosis, and Monitoring of Ovarian Cancer. Cancer Epide- miol Biomarkers Prey, 2012, 21: 1902- 1912.
  • 5Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol, 2008, 108: 402 - 408.
  • 6Ren J, Cai H, Li Y, et al. Tumor markers for early detection of ovarian cancer. Expert Rev Mol Dian, 2010, 10:787 - 798.
  • 7NCCN clincal practice guidelines in ontology, Ovarian Cancer, including fallopian tube tumor and primary peritoneal cancer. 2014.
  • 8Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/ EORTC 55955): a randomized trial. Lancet, 2010, 376: 1155 - 1163.
  • 9Chang X, Ye X, Dong L, et al. Human Epididymis Protein 4 (HFA) as a Serum Tumor Biomarker in Patients With Ovarian Carcinoma. Int J Gynecol Cancer, 2011, 21:852 - 858.
  • 10Yang Z, Luo Z, Zhao B, et al. Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer. Oncol Lett, 2013, 6: 28 - 34.

引证文献6

二级引证文献32

中国妇产科临床杂志
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部